MyChesCo on MSN4h
Ocugen Advances Stargardt Disease Trial with Promising Gene Therapy
(NASDAQ: OCGN) has announced a significant development in its efforts to treat Stargardt disease, as the Data and Safety Monitoring Board (DSMB) has greenlit the enrollment for the second phase of ...
Gene signature to tailor chemotherapy shows promise for improving breast cancer survival
Using a gene signature technique to tailor chemotherapy for patients with early triple negative breast cancer shows promise ...
Long Island Press6h
$430M BioGenesis Park To Put Long Island At Forefront Of Cell Therapy
Gov. Kathy Hochul announced plans to build a $430 million New York BioGenesis Park — a cell and gene therapy lab — in Lake ...
Maine Public6h
Breakthrough technology from the Jackson Laboratory could treat Alzheimers, other diseases
The team has developed synthetic 'DNA switches' that can control genes in certain cells. It's believed the technology could ...
Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development
Sangamo's phase 1/2 STARR study data using isaralgagene civaparvovec targeting patients with Fabry Disease is expected in H1 2025. Learn more on SGMO stock here.
Science Daily8h
Researchers flip genes on and off with AI-designed DNA switches
Researchers have used artificial intelligence to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types. Their new approach opens the ...
GEN8h
AI-Designed DNA Switches Flips Gene Expression On and Off
Researchers used AI to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types.
FiercePharma11h
Roche's Vabysmo will rise above Eylea biosim threat, exec says, as DMD gene therapy Elevidys delivers sales surprise
By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...
BioSpace13h
Sangamo’s Fabry Gene Therapy Could Hit Market 3 Years Earlier With FDA Accelerated Approval Pathway
The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy ...
labiotech13h
RNA editing in humans: the race begins with first successful trial
RNA editing has picked up steam in recent years as a potentially safer alternative to gene editing to treat genetic diseases.
FierceBiotech17h
Ocuphire Pharma to transform into gene-therapy-focused biotech via Opus acquisition
Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...